About EMIG 2 2017-11-11T18:17:59+00:00

Who We Are

EMIG is a multi-stakeholder network and trade industry association that represents the interests of the full span of life sciences companies in the UK. Our industry Members, range from new business start-ups focused on R&D, through to well-established companies delivering a wide range of essential medicines to patients.

Our Members

EMIG Members supply 50% of branded medicines, by volume, to the NHS.

EMIG is the sole representative body of 90% of its Members.

Collaboration

EMIG has over 270 Member Companies and organisations – including Associate Members drawn from academia, patient organisations, learned societies and companies providing essential support services to the Life Sciences ecosystem. Collectively we represent the breadth of the health and medicines ecosystem, from research, clinical development and manufacturing, through to patient charities, research policy organisations and academic institutions. This means EMIG has become a platform for greater knowledge and ideas exchange.

EMIG is a member of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE).

EMIG Members List

A
Academy of Medical Sciences
Accord Healthcare
Actavis
Action Duchenne
Action on Hearing Loss
Addex Therapeutics
Aegerion Pharma
Aguettant UK Ltd
Akcea Therapeutics
Alan Pharmaceuticals
Alexion Pharmaceuticals
Alison Campbell Associates
Alkaptonuria Society
Allergan Ltd
Alliance Pharma plc
Almirall
Altacor Pharma Ltd
Amicus Therapeutics
Amyloidosis Research Consortium
Andrew Carr Associates
APCER Pharma Europe Ltd
Apodi
ApoPharma Inc
Applied Driving Techniques
Aqix
Aquila Biolabs
Aspire Pharma
Association of Medical Research Charities
Astellas
Avillion
Avitus Group
Axess Ltd
Axis Healthcare Consulting

B

Baxter
BGP Products Ltd (Mylan)
Bial Pharma
BioCryst Pharmaceuticals
Biofilm
Bionical
Biotest UK Ltd
Birmingham Health Partners
Bloom Health Ltd
Blue Chip Healthcare
Bob Hackett Training Consultancy
Bowater Holographics
Brabant Pharma
Brancaster Pharma
Britannia Pharmaceuticals
British Liver Trust
Business France

C

C&C Group
Cambridge Enterprise
Cambridge Healthcare
Cambridge Rare Disease Network
Campbell Charles Associates (2000) Ltd
Cancer52
Cancer Research UK
capture1
Cegedim
Celdra Ltd
Celgene
Chantrey Vellacott
Charlwood Pharma
Chiesi Pharmaceuticals
Clarity Pharma Ltd
Clinical Professionals
Clinimed
Cognicept
Concordia
Conseptua Training & Consulting
Consilient Health
Corbett Keeling
Crawford Pharma
Creo Pharma
CSL Behring
Custom Healthcare
Cystic Fibrosis Trust

D

Daiichi Sankyo
Daniel and Daisy Novel Therapeutics Ltd
Davies Consulting
Dee Pharmaceuticals Ltd
Derma UK
Dermal Laboratories Ltd
Desitin Pharma
Dexcel Pharma
Diabetes Professional Care
Dierks & Bohle Attorneys
Discovery Pharmaceuticals
Dr Falk Pharma UK Ltd
DRG – Decision Resources Group
Dr Reddy’s

E

Equa Pharma Ltd
ESMS Global – Emergency Scientific & Medical Services
Ethypharm
European Association for Logistics and Transportation in Healthcare
European Confederation of Pharmaceutical Entrepreneurs
EUSA Pharma
Eventum Partners

F

Ferring Pharmaceuticals Ltd
Fight for Sight
Findacure
Firefly
Four Health Communications
FTI Consulting
Funding Neuro

G

Galderma (UK) Ltd
Gedeon Richter
Genetic Alliance
Genetic Disorders UK
Genomics England
Genzyme Therapeutics Ltd
GFK
Gilead Sciences Int ltd
Grifols UK Ltd
Guerbet Laboratories
GW Pharmaceuticals

H

Healthcare at Home
healx
Healthcare Business Managers Group
Helm Pharmaceuticals
Henry Schein UK Holdings Ltd
HFA Healthcare Products Ltd
Horizon Pharma
HRA Pharma Ltd

I

Idea Pharma
Illingworth Research
Imanova
Imperial College London
IMS Health
Incyte
Intercept Pharmaceuticals
InteRea Ltd
International Health Partners
Internis Pharma
Intrapharm Laboratories
Inventiv Health

J

Jango Communications
Jazz Pharmaceuticals
Jenson R+
Top
K
Kidney Research UK
King’s Health Partners
Kowa Research Europe Ltd
Kyowa Kirin
Top
L
Leadiant Biosciences
Leicester School of Pharmacy, De Montfort University
Leukaemia CARE
LFB Biopharmaceuticals
Logixx Pharma Ltd
Lucane Pharma SA
Top
M
M3
Makara Health Communications
Making Pharmaceuticals
Map BioPharma
Martindale Pharma
MASTA
Masters Global Pharma
MaimoniDex RA Ltd/MaimoniDex (UK) Ltd
MedDay Pharmaceuticals
Medical Research Council Technology
Merz Pharma Ltd
Moorfields Pharmaceuticals
Muscular Dystrophy Campaign
Myeloma UK
Top
N
National Clinical Homecare Association
NHS Confederation
National Services for Health Improvement
National Voices
Neoceuticals
Neonavitas
Neubourg Pharma UK
Network Pharma
NHS Alliance
Nordic Pharma
Norgine
North 51
Novasecta
Nycomed: A Takeda Company
Top
O
OBN
Octapharma
Open Health
Orion Pharma
Orphan Insight Ltd
OUTiCO Ltd
Top
P
ParaPharm Development
Patients Direct
Penlan Healthcare Ltd
Pharma Solutions
Pharmacloud
Pharmaceutical Marketing Society
PharmacoMedics
Pharmexx
Pharmiweb Solutions
pi2 Health
Pierre Fabre
Pinsent Masons
Polycystic Kidney Disease Charity
Plymouth University
Precision Medicine Catapult
Premier Research
Present Value Ltd
Primius Lab Ltd
Top
Q
Quantum Pharma
Queen Mary University of London

R

Rapidscan Pharma Solutions
Raptor Pharmaceuticals Europe
Rare Disease UK
Rarer Cancers Foundation
Real Regulatory
Roboleo & Co
Rocket Science Consultancy
Rouse
Royal Society of Biology

S

Sandoz
Santhera Pharmaceuticals
Sciensus Ltd
Seek Pharma
Servier Laboratories Ltd
Sigma-Tau Pharmaceuticals
Sinclair IS Pharma
Soar Beyond
Spargonet
Spark Therapeutics
Speciality European Pharma Ltd
SpePharm
Spirit Healthcare
ST&I Partnerships Ltd
Star Medical
Stirling Anglian Pharmaceuticals
Stratagem+ Ltd
Structural Genomics Consortium, Oxford University
Substipharm
Sucampo
Surepharm Services Ltd
SwedenBIO
Swedish Orphan Biovitrum Ltd
Top
T
Tanner Pharma
Targeted Solutions Ltd
Technology4Events Ltd
Teijin Pharma
Teva
The Alkaptonuria Society
The Institute of Cancer Research
The M.E. Trust
Thea Pharmaceuticals
The Medical Research Network
The Urology Company Ltd
Thornton & Ross Pharmaceuticals
Tillotts Pharma (UK) Ltd
TLP Delivers
TRAC Services
Typharm Ltd
Top
U
UCL Business
UCL Partners
UK Innovation Forum
United Therapeutics
Universities UK
University of Bristol
University of Leicester
University of Manchester
University of Southampton, Research & Innovation Services
University of Wolverhampton
Top
V
Valuebase
V Pharma
Vectura
Veale Wasbrough Vizards
Vidant Pharma
Vifor Pharma
VISUfarma
Top
W
Wave Data Ltd
Whately-Smith Ltd
Williams Medical Supplies
Wilmington Healthcare
Wyndham Hynds Ltd
Top
X
Xiota
Top
Y
Top
Z
Zebra26 Ltd
Zenopa
Zogenix

What We Do

EMIG enables members to network and meet like-minded professionals who experience the same industry challenges

David Bloomfield

All our Special Interest Group meets three times a year in central London and any member is entitled to join.

Darren Spevick

EMIG represents its Members on the issues directly affecting their businesses.

Leslie Galloway

How we work

EMIG Steering Group
  • The Steering Group oversees the operation of the organisation, its priorities and work programme, and is led by our Chairman, Leslie Galloway. We are unique among life sciences trade associations in that we have a patient organisation representative on the Group.
  • Members of the EMIG Steering Group include our Chairman, Leslie Galloway, Vice Chairman, Abid Karim, Legal Advisor Paul Ranson, Eric Low OBE of the Amyloidosis Research Consortium, and 12 heads of Member Companies.
  • Our policy is ‘One Member – One Vote’. This means our work programme can be developed and approved by the full breadth of our Membership, with full transparency.

Save

Save

Save

Save

Save

Save

Save

Save

EMIG Projects & Collaborations

  • EMIG is committed to collaborative working with academia, charities, patient groups and research-focused bodies to encourage scientific research and innovation in the UK. Better Research for Better Outcomes is an initiative joining up stakeholders from these communities to lead a work programme that seeks to develop a UK value framework for better research.
  • Through EMIG’s Medical Directors Forum, we enable all types of Member organisations to work for collaborative advantage, to encourage the sharing of pre-competitive data and best practices, and to ensure that knowledge, innovation and enterprise can be effectively curated within our part of the life sciences sector in the UK.
  • EMIG works alongside our trade association colleagues in life sciences on shared issues.
Special Interest Groups
We have a number of Special Interest Groups (SIGs) to reflect the differing interests and needs of the myriad roles that make a successful biopharmaceutical company. SIGs meet quarterly and inform EMIG positions on a wide range of issues, from regulation and research, to pricing and orphan diseases.
Each Group has a Chair and the Group determines the content of each meeting agenda.
All our SIGs meet quarterly, mostly in central London, and any Member is entitled to join. Policy proposals made by the SIGs are reviewed by the EMIG Steering Group, and ratified by the Membership, often at our Quarterly Meetings throughout the year.
See how our Special Interest Groups can benefit you:
JOIN EMIG
EMIG has the following Special Interest Groups:
Business Development

The EMIG Business Development group is a networking meeting for those members focussed on building their business by M&A, licensing, partnering and novel in market strategies.

The group meets quarterly at the Manor, Weston on the Green, Oxfordshire. Every meeting starts with a networking lunch followed by an afternoon of interesting content which might typically include:

  • A member company showcasing their business and strategy
  • Case histories of deals completed
  • Contemporary topics affecting the marketplace
  • Professional advice & services from member companies

Many delegates choose to stay for the networking dinner and overnight.

The group was established in 2010 and has become a firm fixture on the UK business development calendar.

Save

Save

Save

Save

Digital

The EMIG Digital Health Group is a networking meeting for those members focused on understanding the latest developments in digital health and going “beyond the pill”.  

The group meets 3 times a year, typically in London. Every meeting starts with a networking coffee followed by a few hours of interesting content which might typically include presentations by:

  • members on what they are doing in digital health
  • digital health companies
  • other relevant stakeholders e.g., NHS Digital, digitalhealth.london, MHRA etc

The group was established in 2016 to meet the need within this new environment. 


Finance

The finance group brings together colleagues from across the finance community of member companies on a quarterly basis to learn, debate and help shape the critical topics and issues affecting the industry from a finance perspective.

The finance group is focussed on offering members an opportunity to…

  • network and meet like-minded professionals who experience the same industry challenges
  • gain knowledge and learn, with presentations and talks that are focussed on our needs
  • have a sounding board for practical issues and give support to others
  • learn from others experiences and explore different approaches
  • debate the important topics
HR

The EMIG HR Group meets four times per year in London and provides a great opportunity for HR Professionals to come together for networking and the exchange and sharing of information and new ideas.

We regularly feature external speakers and the members have the opportunity to agree future topics to be explored at future meetings. We also offer members the opportunity to:

  • learn from others experiences and explore different approaches
  • gain knowledge and learn, with presentations and talks that are focussed on our needs
  • network and meet like-minded professionals who experience the same industry challenges
  • debate the important topics
  • have a sounding board for practical issues and give support to others
Compliance

With a seemingly endless flow of legislative initiatives from Brussels and the need for the UK Government to implement such changes, it has never been more important to keep up with these developments – current issues include pricing and reimbursement transparency, data protection, medical devices approval and safety, biosimilars and rare diseases. This is in addition to other changes that impact on companies more widely such as competition law, EU employment developments, bribery and corruption, tax and patents and other intellectual property.

So that EMIG members can keep up to date with changes that most affect their business Pinsent Masons LLP and Alexander Natz, Secretary-General of EUCOPE have agreed to establish and run a quarterly EU and Legal Issues Special Interest Group. The aim will be to review recent and forthcoming changes and discuss in depth issues where Governmentconsultation is ongoing or where urgent action may be necessary.

Meetings will be held at Pinsent Masons’ offices in the City. Further details including the agenda will be sent out by way of a reminder nearer the time.


Market Access

The Market Access Group aims to:

  • Reduce the hurdles to uptake in the UK and enable innovative products to reach patients in a timely manner

  • Identify cost-effective solutions to market access challenges

  • Work with government and officials to communicate solutions to market access challenges

  • Understand the impact on the varied range of EMIG member companies (biotechs to mature companies) of gaining market access in the UK

Medical Directors’ Forum

The EMIG Medical Directors’ Forum aims:

  • To promote a scientific and medical research policy and operating environment that supports optimally the growth and sustainability of small to medium-sized pharmaceutical companies.

  • To identify and access new opportunities for technology development with academia and the NHS.

  • To build an innovative open platform for knowledge exchange and collaboration between diverse life sciences organisations

Northern Ireland
Regulatory

The EMIG Regulatory group hold regular information sharing and networking meetings for those members working in Regulatory Affairs, related disciplines or those with an interest in understanding more about current challenges impacting the industry.

The group meets at least three time a year in London.  Each meeting focuses on current hot topics and take the form of presentations and/or group discussions. External experts and Regulatory Authority personnel are often invited as appropriate.  Examples of recent topics include:

  • GMP/GDP – led by MHRA inspectorate
  • Source Transfer Masterclass – group discussion around current challenges
  • Patient Information

Events are a valuable networking opportunity, with time allocated at the start of each session for informal networking.

In addition, the EMIG Regulatory group takes the lead on two key MHRA meetings for our membership:

  • Cross trade meeting
  • Bi-lateral meeting

The group was established in 2008 and is developing along with EMIG member requirements to ensure it has value for all.

Scotland

Scotland Group focuses on issues including:

  • Co-operation with the Scottish Lifesciences Association

  • Engagement with SMC and how we can reduce the cost of SMC submissions for SMEs

  • SMC position on uptake – clinical standards

  • CEL 17 and the question of how it needs to be implemented in Health Boards

  • Planning post-election engagement with the new political encumbents

Wales

Wales Group was established to:

  • Provide a voice for members in Wales

  • Build relations with the All Wales Medicines Strategy Group and with key stakeholders in the Welsh Assembly

  • Engage with the Bio Industry Association (BIA) in Wales.

EMIG’s mission

“We work closely with government, regulators, HTA bodies, academia, medical research organisations and the NHS to advance patient access to the most effective and innovative medicines; to promote the UK as an attractive environment for research and investment; and to enhance our Members’ ability to operate effectively.”

 

 

Save

Save

Save

Save

Save

Save

Save

Our Values

In pursuing our mission we strive to be:

  • Patient-centred

  • Accountable

  • Results focused

  • Collaborative

  • Innovative

  • Evidence-based

  • Open

 

Save

Save

Save

Save

Save

Save

Save